cefaclor
Trade name: ceclor
Approved
Apr 4, 1979
Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 12 marketing orgs
Earliest trial started Jun 1, 2022 (NCT05398679)
Timeline
1970s
1990s
- Apr 27, 1995
DAVA Pharmaceuticals — Marketing Organization
- Apr 27, 1995
Teva — Marketing Organization
- May 23, 1996
Watson Pharmaceuticals — Marketing Organization
- May 23, 1996
Heritage Pharma — Marketing Organization
- May 23, 1996
Chartwell Pharmaceuticals — Marketing Organization
- Aug 28, 1997
Ranbaxy — Marketing Organization
2000s
- Jan 5, 2001
Genelabs Technologies — Marketing Organization
- Jan 22, 2004
Yung Shin Pharm. Ind. Co., Ltd. — Marketing Organization
- Apr 3, 2007
Hikma — Marketing Organization
Indications
Approved for
Studied for
Mechanism of action
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Approval history
- approvedApr 4, 1979
Chemistry & pharmacology
SMILES
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1- Mol. weight
- 367.81 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL680 ↗
- WikipediaCefaclor ↗
- NCATS3Z6FS3IK0K ↗
- ChEMBLCHEMBL1201018 ↗
Also known as
- 3-chloro-7-d-(2-phenylglycinamido)-3-cephem-4-carboxylic acid
- 3-chloro-7-d-(2-phenylglycinamido)-3-cephem-4-carboxylic acid
- alfacet
- bacticlor mr
- ccl
- ccl
- ceclor
- ceclor
- ceclor
- ceclor
- ceclor cd
- ceclor cd
- cefaclor
- cefaclor
- cefaclor
- cefaclor
- cefaclor
- cefaclor
- cefaclor
- cefaclor
- cefaclor
- cefaclor
- cefaclor anhydrous
- cefaclor anhydrous
- cefaclor hydrate
- cefaclor hydrate
- cefaclor hydrate
- cefacloro
- cefacloro
- cefaclorum
- cefaclorum
- céfeaclor
- céfeaclor
- cephaclor
- cephaclor
- cephaclor
- compound 99638
- compound 99638
- distaclor
- distaclor
- distaclor
- distaclor mr
- keftid
- losefar
- raniclor
- raniclor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05398679 | Phase 4 | Jun 1, 2022 | University of Barcelona |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Barcelona | Academic/Hospital | 1 | 1 | 1 | 2022 |
Marketing (14)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Ceph Intl | For profit | MKTG | Jul 28, 1979 |
| Chartwell Pharmaceuticals | For profit | MKTG | May 23, 1996 |
| DAVA Pharmaceuticals | For profit | MKTG | Apr 27, 1995 |
| Eli Lilly | For profit | NDA | Apr 4, 1979 |
| Genelabs Technologies | For profit | MKTG | Jan 5, 2001 |
| Heritage Pharma | For profit | MKTG | May 23, 1996 |
| Hikma | For profit | MKTG | Apr 3, 2007 |
| Ranbaxy | For profit | MKTG | Aug 28, 1997 |
| Ranbaxy | For profit | SYN | Dec 22, 2003 |
| Teva | For profit | MKTG | Apr 27, 1995 |
| Teva | For profit | SYN | Jun 24, 1996 |
| Watson Pharmaceuticals | For profit | MKTG | May 23, 1996 |
| Yung Shin Pharm. Ind. Co., Ltd. | For profit | MKTG | Jan 22, 2004 |
| facta | For profit | MKTG | Apr 23, 1979 |